Tin tức & Cập nhật

Enteral ecoimmunonutrition confers benefits on patients undergoing hepatectomy

23 Feb 2022

In patients undergoing hepatectomy, an intervention with enteral ecoimmunonutrition (EEIN) support appears to protect liver function, reduce serum endotoxin levels and inflammatory factors, improve immune function, and promote the recovery of postoperative gastrointestinal function, according to a recent study. These findings prove that EEIN support is viable for clinical application.

Enteral ecoimmunonutrition confers benefits on patients undergoing hepatectomy

23 Feb 2022

Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?

23 Feb 2022 bởi

In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.

Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?

23 Feb 2022

Intrahepatic lipid content tied to soluble E-selectin levels

19 Feb 2022

At a population level, intrahepatic lipid (IHL) content seems to be a significant and independent predictor of soluble E-selectin (sE-selectin) levels, a recent study suggests.

Intrahepatic lipid content tied to soluble E-selectin levels

19 Feb 2022

Overt hepatic encephalopathy predisposes cirrhotic patients with AD to de novo infection

18 Feb 2022

Cirrhotic patients with acute decompensation (AD) are at heightened risk of de novo infection during hospitalization, specifically in the presence of overt hepatic encephalopathy, a study has found.

Overt hepatic encephalopathy predisposes cirrhotic patients with AD to de novo infection

18 Feb 2022

NAFLD does not raise severe COVID-19 risk

11 Feb 2022

There is no causal relationship between genetic predisposition to nonalcoholic fatty liver disease (NAFLD) and increased risk of developing severe COVID-19, according to a Mendelian randomization study.

NAFLD does not raise severe COVID-19 risk

11 Feb 2022

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal

06 Feb 2022

The chances of hepatitis B surface antigen (HBsAg) loss after withdrawing nucleo(s)tide analogue (NUC) treatment depend on factors such as patient ethnicity, end-of-treatment antigen levels, and HBV genotype, a new study reports.

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal

06 Feb 2022

Hepatitis E virus resistant to alcohol-based disinfectants

06 Feb 2022

Alcohol-based hand disinfectants might be insufficient to suppress hepatitis E virus infectivity, a new study has found.

Hepatitis E virus resistant to alcohol-based disinfectants

06 Feb 2022

FVIII/PC predicts complication risk in ACLD, but not coagulation potential

27 Jan 2022

In patients with advanced chronic liver disease (ACLD), ratio of procoagulant factor VIII to anticoagulant protein C (FVIII/PC) is significantly prognostic of decompensation, death, and acute-on-chronic liver failure (ACLF), a new study has found. However, FVIII/PC is not related to thrombosis and does not reflect coagulation.

FVIII/PC predicts complication risk in ACLD, but not coagulation potential

27 Jan 2022

$Tailor refractory ascites treatment according to patient context, study says$

Tailor refractory ascites treatment according to patient context, study says

23 Jan 2022

Refractory ascites is a severe complication of liver cirrhosis leading to poor prognosis and is curable only through liver transplantation, reports a recent meta-analysis.

Tailor refractory ascites treatment according to patient context, study says

23 Jan 2022

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

21 Jan 2022

Among patients with nonalcoholic fatty liver disease (NAFLD), the more severe the liver fibrosis, the higher the risk of developing extrahepatic events, a study has found. Specifically, the risk is low among patients with mild fibrosis, low but clinically relevant among those with moderate fibrosis, and high among those with severe to advanced fibrosis.

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

21 Jan 2022

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Enteral ecoimmunonutrition confers benefits on patients undergoing hepatectomy

Enteral ecoimmunonutrition confers benefits on patients undergoing hepatectomy

Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?

Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?

Intrahepatic lipid content tied to soluble E-selectin levels

Intrahepatic lipid content tied to soluble E-selectin levels

Overt hepatic encephalopathy predisposes cirrhotic patients with AD to de novo infection

Overt hepatic encephalopathy predisposes cirrhotic patients with AD to de novo infection

NAFLD does not raise severe COVID-19 risk

NAFLD does not raise severe COVID-19 risk

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal

Hepatitis E virus resistant to alcohol-based disinfectants

Hepatitis E virus resistant to alcohol-based disinfectants

FVIII/PC predicts complication risk in ACLD, but not coagulation potential

FVIII/PC predicts complication risk in ACLD, but not coagulation potential

Tailor refractory ascites treatment according to patient context, study says

Tailor refractory ascites treatment according to patient context, study says

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

Risk of extrahepatic events high among NAFLD patients with severe liver scarring